sotorasib,docetaxel
amgen,sanofi,aventis
['sotorasib', 'nsclc', 'codebreak 200', 'sclc', 'docetaxel']
#esmo22 highlight: in phase iii trial codebreak 200, sotorasib was well tolerated and demonstrated a superior pfs across all subgroups to soc docetaxel in previously treated nsclc with kras g12c mutation. exciting result that emphasizes the growing importance of ngs testing! 